Nanomedicine is the fusion between drug therapy and nanotechnology. It is an expanding industry which provides a more efficient and effective way to deliver drugs throughout the body. For individuals suffering from a neurodegenerative disorder, like Huntington’s Disease (HD), current treatments cause major side effects in addition to the disease’s detrimental motor, behavioral and psychiatric symptoms. The goal of the experiment is to encapsulate tetrabenazine, the only FDA approved drug for HD, in a nanoparticle called a micelle. If successful, the new drug nanoparticle can undergo animal testing then clinical trials in hopes of improving patients’ lives.
| Identifer | oai:union.ndltd.org:CLAREMONT/oai:scholarship.claremont.edu:cmc_theses-2790 |
| Date | 01 January 2018 |
| Creators | Severt, Kailee |
| Publisher | Scholarship @ Claremont |
| Source Sets | Claremont Colleges |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | CMC Senior Theses |
| Rights | © 2017 Kailee A. Severt, default |
Page generated in 0.0023 seconds